A Senate bill was touted as a cure for ‘patent thickets.’ Some say the drug industry watered it down

Taking stock of the drug industry, from the lab to the medicine chest

July 17, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | A Senate bill was touted as a cure for 'patent thickets.' Some say the drug industry watered it down Designed to cut drug prices through greater competition, the Affordable Prescriptions for Patients Act is "a shadow of its former self," one expert said. By Ed Silverman and Rachel Cohrs Zhang STAT+ | Gilead's chief medical officer to leave as R&D efforts stall Merdad Parsey, who joined Gilead in 2019, will stay in his post until the first quarter of next year as the company looks for a successor, Gilead said. By Elaine Chen STAT+ | A second Roche obesity drug shows promise in early studies The drug, called CT-996, is one of several experimental medicines Roche is advancing as it tries to enter the booming obesity medicine field. By Andrew Joseph Eddie Quinones for STAT As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them The diabetes community fears the drugmakers, which have long provided insulin, are prioritizing the development and sale of GLP-1 weight loss medications. By Elaine Chen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser